⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ONL News
Orion Properties Inc.
ONL Therapeutics Announces First European Patient Randomized in its Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD
prnewswire.com
ONL
Form 8-K
sec.gov
ONL
Orion Properties Inc. Announces Fourth Quarter and Full Year 2025 Results
businesswire.com
ONL
O
Form 8-K
sec.gov
ONL
Orion Properties Inc. Positioned For Continued Business Plan Execution With New $215 Million Revolving Facility and Extension of $355 Million CMBS Loan
businesswire.com
ONL
O
Orion Properties Inc. Announces Tax Treatment of 2025 Dividends
businesswire.com
ONL
O
Orion Properties Announces Strategic Options Review Process to Maximize Stockholder Value
businesswire.com
ONL
Orion Properties Announces that Director Nomination Notice from Kawa is Invalid
businesswire.com
ONL
O
Orion Properties Confirms Receipt of Director Nominees
businesswire.com
ONL
O
Orion Properties Inc. Announces Third Quarter 2025 Results
businesswire.com
ONL
O